Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30365712 | 1.00 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL8763608 | 0.82 | TSHR (0.42) | CA1CA2ALDH1A1HPGDTSHR | |
| SCHEMBL10954000 | 0.81 | SLC6A4 (0.45) | ALDH1A1TSHRKMT2AHTTL3MBTL1 | |
| SCHEMBL3292456 | 0.81 | ALDH1A1 (0.34) | ALDH1A1KDM4ESGMS2SMN1; SMN2MAPT | |
| SCHEMBL28664064 | 0.81 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10635074 | 0.80 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3807954 | 0.80 | PTGS2 (0.47) | ALDH1A1ACHEKDM4EHPGDHSD17B10 | |
| SCHEMBL2937140 | 0.80 | PTGS2 (0.47) | ALDH1A1ACHEKDM4EHPGDHSD17B10 | |
| SCHEMBL21656102 | 0.80 | DHFR (0.38) | KDM4E | |
| SCHEMBL21656555 | 0.80 | HTR2A (0.38) | ALDH1A1ACHEKDM4ESMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110845364-B | Preparation method of nitrile compound with formamide as cyanogen source | 湘潭大学 | 2023-02-03 | — | — | CN | disclosed |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| CN-110845364-A | Preparation method of nitrile compound with formamide as cyanogen source | 湘潭大学 | 2020-02-28 | — | — | CN | disclosed |
| EP-3609869-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
| CN-110730776-A | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and their use | 拜耳股份公司 | 2020-01-24 | — | — | CN | disclosed |
| WO-2018189011-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-10-18 | — | — | WO | disclosed |
| EP-2261327-B1 | A group of novel enantioselective microbial nitrile hydratases with broad substrate specificity | B R A I N AG (DE) | 2013-11-20 | — | — | EP | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2261327-A2 | A group of novel enantioselective microbial nitrile hydratases with broad substrate specificity | B.R.A.I.N. AG (DE) | 2010-12-15 | — | — | EP | disclosed |
| EP-2004814-B1 | A GROUP OF NOVEL ENANTIOSELECTIVE MICROBIAL NITRILE HYDRATASES WITH BROAD SUBSTRATE SPECIFICITY | B R A I N AG (DE) | 2010-09-08 | — | — | EP | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| EP-1842907-A1 | A group of novel enantioselective microbial nitrile hydratases with broad substrate specificity | B.R.A.I.N. AG (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | CA1 4617/4885CA2 3008/4885CA7 3893/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | CA1 4617/4885CA2 3008/4885CA7 3893/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | CA1 4157/4885CA2 2270/4885CA7 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.